Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 51

Sort by

Sort Order Select

Journal Articles

Fast Onset of Action of Subcutaneously Administered Marzeptacog Alfa (Activated) Supports on-Demand Treatment in Hemophilia a Mice

Frank Del Greco, MBA, Linda Neuman, MD, Howard Levy, PhD MBBChir, Jill Reckless, Tom Knudsen, PhD DVM, Grant E. Blouse, PhD

Blood (2019) 134 (Supplement_1): 2420.

https://doi.org/10.1182/blood-2019-128971

Published: 2019

Journal Articles

Highly Potent BTK Degradation Induced By NRX0492 As a Therapeutic Strategy for CLL

Deyi Zhang, PhD, Hailey Harris, Aileen Kelly, PhD, Daniel W Robbins, May Tan, Timothy Ingallinera, Neil Bence, Arthur T Sands, Sivasubramanian Baskar, Sarah E. M. Herman, Adrian Wiestner, MD PhD

Blood (2019) 134 (Supplement_1): 174.

https://doi.org/10.1182/blood-2019-126921

Published: 2019

Journal Articles

Antileukemic Activity of 8-Chloro-Adenosine (8-Cl-Ado) Is Mediated By Mir-155 Degradation and ErbB3 Binding Protein (Ebp1)-Dependent p53 Activation: A Novel Therapeutic Approach for FLT3-ITD Acute Myeloid Leukemia (AML)

Blood (2018) 132 (Supplement 1): 3938.

https://doi.org/10.1182/blood-2018-99-119880

Published: 2018

Journal Articles

Data Coming out of the Human Inhibitor PUP Study (HIPS) Reveal 4 Subgroups of Patients with Distinct Antibody Signatures

Blood (2018) 132 (Supplement 1): 3774.

https://doi.org/10.1182/blood-2018-99-115979

Published: 2018

Journal Articles

Breaking IL7R Signaling-Induced Glucocorticoid Resistance By Small Molecule Inhibitors in T-Cell Acute Lymphoblastic Leukemia

Jordy Van Der Zwet, MD, Jules Meijerink, PhD, Jessica Buijs-Gladdines, Yunlei Li, PhD, Rob Pieters, MD PhD

Blood (2017) 130 (Supplement 1): 2534.

https://doi.org/10.1182/blood.V130.Suppl_1.2534.2534

Published: 2017

Journal Articles

The Novel Thiosemicarbazone Derivative Coti-2 Induces Mitochondrial Apoptosis in Acute Myeloid Leukemia Cells Via a p53-Independent Mechanism

Dhruv Chachad, Jo Ishizawa, MD PhD, Wayne R Danter, MD, Gordon Mills, MD PhD, Michael Andreeff, MD PhD, Kensuke Kojima, MD, PhD

Blood (2016) 128 (22): 2757.

https://doi.org/10.1182/blood.V128.22.2757.2757

Published: 2016

Journal Articles

8-Chloro-Adenosine Inhibits Molecular Poor-Risk Acute Myeloid Leukemia (AML) and Leukemic Stem Cells (LSC) Growth and Synergizes with the BCL-2 Inhibitor Venetoclax (ABT-199)

Ralf Buettner, PhD, Ching-Cheng Chen, PhD, Bijender Kumar, PhD, Corey Morales, BA, BS, Lisa S Chen, PhD, Krister Wennerberg, PhD, Ryan Thompson, MS, Tea Pemovska, MSc, Ling Li, PhD, Bin Zhang, PhD, Claudia Kowolik, PhD, Mika Kontro, MD, Calum Leitch, MD, David Horne, PhD, Joycelynne Palmer, PhD, Varsha Gandhi, PhD, Guido Marcucci, MD, Vinod Pullarkat, MD, Steven T. Rosen, MD

Blood (2016) 128 (22): 2758.

https://doi.org/10.1182/blood.V128.22.2758.2758

Published: 2016

Journal Articles

The Common PAR4 Ala120Thr Variant Has a Major Effect on Platelet Reactivity to Thrombin and These Effects Are Enhanced with PAR1 and P2Y12 Inhibition

Michael J. Whitley, Joanne Vesci, Michael Holinstat, PhD, Leonard C. Edelstein, PhD, Paul F. Bray, MD

Blood (2016) 128 (22): 709.

https://doi.org/10.1182/blood.V128.22.709.709

Published: 2016

Journal Articles

MYC Inhibition and TP53 Activation Synergistically Suppress Immune Checkpoint Ligand PD-L1 Expression in AML Cells

Joshua B. Bland, B.S., William T. Tse, MD, PhD

Blood (2016) 128 (22): 1667.

https://doi.org/10.1182/blood.V128.22.1667.1667

Published: 2016

Journal Articles

Appearance of High-Affinity Antibodies Precedes Clinical Diagnosis of FVIII Inhibitors - Preliminary Analysis from the Hemophilia Inhibitor PUP Study (HIPS)

Birgit M Reipert, PhD, Bagirath Gangadharan, PhD, Christoph J Hofbauer, PhD, Fritz Scheiflinger, PhD, Joel Bowen, Elizabeth Donnachie, PhD, Karen Fijvandraat, MD, Ralph A. Gruppo, MD, Jenny Klintman, MD PhD, Christoph Male, MD, Catherine E. McGuinn, MD, Shannon L. Meeks, MD, Michael Recht, MD PhD, M V Ragni, MD, Hassan M Yaish, Elena Santagostino, MD PhD, Deborah L Brown, MD

Blood (2016) 128 (22): 328.

https://doi.org/10.1182/blood.V128.22.328.328

Published: 2016

Journal Articles

Inactivating Heat Shock Factor 1 (HSF1) in Acute Myeloid Leukemia By Pharmacological Inhibition of eIF4a: A Promising Therapeutic Approach

Jo Ishizawa, MD PhD, Rodrigo Omar Jacamo, PhD, Kensuke Kojima, MD PhD, Dhruv Chachad, MS, Vivian Ruvolo, MS, Peter Ruvolo, PhD, Weiguo Zang, PhD, Yoko Tabe, MD PhD, Marina Konopleva, MD PhD, William Devine, PhD, Susan Lindquist, PhD, John A Porco, Jr., Luke Whitesell, MD PhD, Michael Andreeff, MD PhD

Blood (2015) 126 (23): 2548.

https://doi.org/10.1182/blood.V126.23.2548.2548

Published: 2015

Journal Articles

Development Of RNAi Therapeutics Targeting The Complement Pathway

Anna Borodovsky, PhD, Kristina Yucius, Andrew Sprague, James Butler, PhD, Shannon Fishman, BS, Tuyen Nguyen, Akshay Vaishnaw, MD, PhD, Martin Maier, PhD, Rajeev Kallanthottathil, PhD, Satya Kuchimanchi, PhD, Muthiah Manoharan, PhD, Rachel Meyers, PhD, Kevin Fitzgerald, PhD

Blood (2013) 122 (21): 2471.

https://doi.org/10.1182/blood.V122.21.2471.2471

Published: 2013

Journal Articles

Synergistic Antileukemic Effect Of Sequential Administration Of Dichloroacetate (DCA) Combined With Arsenic Trioxide (ATO) In Primary Blasts From Patients With Acute Myeloid Leukemia (AML) and FLT3-ITD AML Cell Lines

Ashkan Emadi, M.D., Ph.D., Brandon Carter-Cooper, BS, Mariola Sadowska, PhD, Omasiri Wonodi, BS, Rena G. Lapidus, PhD, Mark Levis, MD, PhD, Edward A. Sausville, MD, PhD

Blood (2013) 122 (21): 3955.

https://doi.org/10.1182/blood.V122.21.3955.3955

Published: 2013

Journal Articles

Expanded Therapeutic Index Of Antithrombin Silencing and Correction Of Aptt In a Hemophilia A Mouse Model

Scott A Barros, PhD, DABT, Mary Carioto, Julia Hettinger, Yongfeng Jiang, June Qin, Harsha Prabhala, Alfica Sehgal, PhD, Akin Akinc, PhD

Blood (2013) 122 (21): 3585.

https://doi.org/10.1182/blood.V122.21.3585.3585

Published: 2013

Journal Articles

Dual Inhibition of JAK/STAT and MAPK Pathways Results in Synergistic Cell Killing of JAK-Mutated Pediatric Acute Lymphoblastic Leukemia

Santi Suryani, PhD, Keith CS Sia, Lauryn Bracken, Hernan Carol, PhD, Kathryn Evans, Raushan Kurmasheva, PhD, Peter J. Houghton, PhD, Malcolm A. Smith, MD, PhD, Richard B. Lock, PhD

Blood (2012) 120 (21): 3562.

https://doi.org/10.1182/blood.V120.21.3562.3562

Published: 2012

Journal Articles

An RNAi Therapeutic Targeting Antithrombin Increases Thrombin Generation in Nonhuman Primates

Akin Akinc, PhD, Alfica Sehgal, PhD, Scott Barros, PhD, Julia Hettinger, Klaus Charisse, PhD, Josh Brodsky, June Qin, Tim Racie

Blood (2012) 120 (21): 3370.

https://doi.org/10.1182/blood.V120.21.3370.3370

Published: 2012

Journal Articles

Dynamic Changes in Platelet Responsiveness to Thrombin and Coated Platelet Potential May Inform Risk of Hemorrhage and/or Thrombosis in a Novel Canine Mode of Immune Thrombocytopenia.

Marshall A. Mazepa, MD, Dana N LeVine, DVM, DACVIM, Adam J Birkenheuer, DVM, PhD, DACVIM, Marjory B Brooks, DVM, DACVIM, Shila K Nordone, PhD, Dwight A Bellinger, DVM, PhD, Sam L Jones, DVM, PhD, DACVIM, Thomas H Fischer, PhD, Jonathan E Fogle, DVM PhD DACVIM, Nigel S Key, MBChB

Blood (2012) 120 (21): 2193.

https://doi.org/10.1182/blood.V120.21.2193.2193

Published: 2012

Journal Articles

The JAK1/2 Inhibitor Ruxolitinib Kills Malignant Plasma Cells and Is Synergistic with PI3K and mToR Inhibitors

Renate Burger, Tim Bugdahn, Matthias Staudinger, Anna Lena Michaelis, Matthias Peipp, Andreas Guenther, Martin Gramatzki

Blood (2012) 120 (21): 1844.

https://doi.org/10.1182/blood.V120.21.1844.1844

Published: 2012

Journal Articles

RNAi-Mediated Inhibition of Activated Protein C- A New Approach for Hemophilia Treatment

Ivanka Toudjarska, PhD, Zuhua Cai, Tim Racie, Julia Hettinger, Stuart Milstein, PhD, Brian R Bettencourt, PhD, Dinah WY Sah, PhD, David Bumcrot, PhD, John Maraganore, PhD, Akshay Vaishnaw, MD, PhD

Blood (2011) 118 (21): 1204.

https://doi.org/10.1182/blood.V118.21.1204.1204

Published: 2011

Journal Articles

The Major Phagocyte Peroxidase-Derived Oxidant HOSCN Stimulates Gene-Specific p38 MAPK- Dependent, NF-κb-Mediated Activation of Tissue Factor, VCAM-1 and ICAM-1 Expression In Endothelium.

Teena Rehani, Ph.D., Adria Jonas, M.S., Arne Slungaard, MD

Blood (2010) 116 (21): 1481.

https://doi.org/10.1182/blood.V116.21.1481.1481

Published: 2010

NARROW

Fast Onset of Action of Subcutaneously Administered Marzeptacog Alfa (Activated) Supports on-Demand Treatment in Hemophilia a Mice

Highly Potent BTK Degradation Induced By NRX0492 As a Therapeutic Strategy for CLL

Antileukemic Activity of 8-Chloro-Adenosine (8-Cl-Ado) Is Mediated By Mir-155 Degradation and ErbB3 Binding Protein (Ebp1)-Dependent p53 Activation: A Novel Therapeutic Approach for FLT3-ITD Acute Myeloid Leukemia (AML)

Data Coming out of the Human Inhibitor PUP Study (HIPS) Reveal 4 Subgroups of Patients with Distinct Antibody Signatures

Breaking IL7R Signaling-Induced Glucocorticoid Resistance By Small Molecule Inhibitors in T-Cell Acute Lymphoblastic Leukemia

The Novel Thiosemicarbazone Derivative Coti-2 Induces Mitochondrial Apoptosis in Acute Myeloid Leukemia Cells Via a p53-Independent Mechanism

8-Chloro-Adenosine Inhibits Molecular Poor-Risk Acute Myeloid Leukemia (AML) and Leukemic Stem Cells (LSC) Growth and Synergizes with the BCL-2 Inhibitor Venetoclax (ABT-199)

The Common PAR4 Ala120Thr Variant Has a Major Effect on Platelet Reactivity to Thrombin and These Effects Are Enhanced with PAR1 and P2Y12 Inhibition

MYC Inhibition and TP53 Activation Synergistically Suppress Immune Checkpoint Ligand PD-L1 Expression in AML Cells

Appearance of High-Affinity Antibodies Precedes Clinical Diagnosis of FVIII Inhibitors - Preliminary Analysis from the Hemophilia Inhibitor PUP Study (HIPS)

Inactivating Heat Shock Factor 1 (HSF1) in Acute Myeloid Leukemia By Pharmacological Inhibition of eIF4a: A Promising Therapeutic Approach

Development Of RNAi Therapeutics Targeting The Complement Pathway

Synergistic Antileukemic Effect Of Sequential Administration Of Dichloroacetate (DCA) Combined With Arsenic Trioxide (ATO) In Primary Blasts From Patients With Acute Myeloid Leukemia (AML) and FLT3-ITD AML Cell Lines

Expanded Therapeutic Index Of Antithrombin Silencing and Correction Of Aptt In a Hemophilia A Mouse Model

Dual Inhibition of JAK/STAT and MAPK Pathways Results in Synergistic Cell Killing of JAK-Mutated Pediatric Acute Lymphoblastic Leukemia

An RNAi Therapeutic Targeting Antithrombin Increases Thrombin Generation in Nonhuman Primates

Dynamic Changes in Platelet Responsiveness to Thrombin and Coated Platelet Potential May Inform Risk of Hemorrhage and/or Thrombosis in a Novel Canine Mode of Immune Thrombocytopenia.

The JAK1/2 Inhibitor Ruxolitinib Kills Malignant Plasma Cells and Is Synergistic with PI3K and mToR Inhibitors

RNAi-Mediated Inhibition of Activated Protein C- A New Approach for Hemophilia Treatment

The Major Phagocyte Peroxidase-Derived Oxidant HOSCN Stimulates Gene-Specific p38 MAPK- Dependent, NF-κb-Mediated Activation of Tissue Factor, VCAM-1 and ICAM-1 Expression In Endothelium.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only